Clinical Trial

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2024-09-24; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-01-23
Trial Details
NCT Number NCT06615479
Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Collaborators: Celgene Corporation
Conditions Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment 440 participants
Start Date 2025-03-12
Primary Completion 2027-12-30 (estimated)
Study Completion 2032-06-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-23